tiprankstipranks
Avacta Advances Cancer Drug Trial, Strengthens Board
Company Announcements

Avacta Advances Cancer Drug Trial, Strengthens Board

Avacta Group plc (GB:AVCT) has released an update.

Don't Miss Our Christmas Offers:

Avacta Group plc has announced the successful completion of the second cohort in the Phase 1 trial of AVA6000, a promising cancer treatment, with dosing underway for the third cohort. With a strong cash position, the company is positioned to advance AVA6000 into Phase 2 trials and further develop its innovative medicine pipeline. Additionally, Avacta has bolstered its leadership with the appointment of Darlene Deptula-Hicks as Non-Executive Director, enhancing its strategic and commercial expertise.

For further insights into GB:AVCT stock, check out TipRanks’ Stock Analysis page.

Related Articles
TipRanks UK Auto-Generated NewsdeskAvacta Group Opens Phase 1b Trial for Targeted Cancer Therapy
TipRanks UK Auto-Generated NewsdeskAvacta Group Advances with Targeted Cancer Therapies
TipRanks UK Auto-Generated NewsdeskAvacta Group Unveils Promising Cancer Therapy Advances
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App